Navigation Links
A leap forward in the quest to develop an artificial pancreas
Date:11/12/2012

A diabetes specialist and Artificial Intelligence expert have collaborated to test the prototype of an artificial pancreas. Should a planned clinical study and clinical trial support the excellent 'simulated' results obtained so far, this breakthrough could one day change the lives of millions of people.

People with type 1 diabetes have insufficient levels of insulin producing cells in their pancreas, or none at all, as a result of an autoimmune attack that is not currently preventable. They must inject or infuse insulin several times a day to control their blood sugar levels. This is a very crude substitute for what the body does moment-by-moment when it senses blood sugar and automatically releases the right amount of insulin to control it. Insulin pumps help with management to some extent, but there is much guesswork involved, as insulin values must be entered manually.

High blood sugars cause damage to tissues and organs, and over a lifetime can lead to very serious complications such as kidney failure and blindness.

As a result, research groups around the world are in a race to develop technologies or techniques that will match the body's incredibly sophisticated use of insulin to control blood sugar levels. JDRF, the leading global organisation focused on type 1 diabetes research, has sought to coordinate and accelerate these efforts through the JDRF Artificial Pancreas Project.

Associate Professor Jenny Gunton from Sydney's Garvan Institute of Medical Research and Dr Nigel Greenwood, an Honorary Senior Fellow at the University of Queensland, received an Innovative Grant from JDRF a year ago to carry out initial tests on the prototype already developed by Dr Greenwood.

Dr Greenwood is the founder of the technology company NeuroTech Research Pty Ltd, for which he developed machine intelligence software called 'Neuromathix'. With funding from the directors of his company, as well as some funding from the Queensland government, he built prototypes in 2009/10 of Neuromathix artificial pancreas software.

Greenwood is an applied mathematician with a background in developing machine intelligence software for military aerospace projects and industrial robotics. Such software analyses data, forms 'hypotheses' or possibilities, tests those hypotheses and acts on them, but interacts with people differently from the usual way that has come to be associated with the phrase 'Artificial Intelligence'.

The JDRF-funded project used two virtual or 'simulated' patients, generated by a 'black box' simulator containing the best models of diabetes from the literature, plus typical parameter values for diabetes. These virtual patients' meal data and insulin data were obtained from actual patients with diabetes. This was fed into the simulator, which then generated their blood glucose levels and other medical data as if they were real people.

The patient information was 'interrogated' by the Neuromathix software. To help itself understand what it was observing, the machine-intelligent software generated a further 2,599 possible diabetic profiles to study and control. Out of the maze of outcomes (the diabetes model spans 15 dimensions and has over 20 parameters that are initially unknown), the software calculated suggested insulin dosages, which were given to the simulated patients. Blood glucose readings were analysed after insulin delivery, over 55 simulated days.

The results of the testing period surprised even Greenwood and Gunton. "Over 55 days of simulated automated insulin therapy, we achieved blood glucose levels within the target interval of 4.4 - 7.8 mmol/L over 90% of the time overall, and we achieved the target 99.8% of the time in the two simulated patients' main case studies, which is extraordinary because the average person with diabetes would be outside that range over 60% of the time," said Greenwood.

"What we have just done couldn't have been done 10 years ago - we are dealing with a profoundly complex model involving many unknowns. For each patient, the software would explore about 15 million different possibilities so as you can imagine, we relied on high performance computing. We used a desktop supercomputer something that didn't even exist before 2007."

"The ultimate aim for a 'mechanical cure' for type 1 diabetes would be to have a closed loop system where you have an insulin pump which knows how much insulin to give at the right time," said Associate Professor Gunton.

"So you have glucose monitoring and insulin administration in the same machine with very smart pump software keeping people's blood glucose normal."

"The technology we just tested is revolutionary for a whole lot of mathematical reasons but the point is that it forecasts a completely new approach to programming insulin pumps, with the results from this preliminary grant being extremely impressive."

Greenwood is aiming to reach the market by the end of 2016. He is fundraising at the moment to do a small clinical study next year and a clinical trial in 2014.

"The second trial will be much bigger we'll be trying to establish not only that our software works on actual people with diabetes, but that it's the best in the world," he said.

JDRF's Head of Research Development Dr Dorota Pawlak said type 1 diabetes is a complex disease that demands coordinated research.

"Combining diabetes expertise with mathematical innovation, this project draws on resources more commonly found in the military or robotics industries, and applies them to the next big diabetes breakthrough, an artificial pancreas."

"This approach to modelling possible human outcomes could expedite some of the lengthy and expensive steps of research that would usually be required."


'/>"/>
Contact: Alison Heather
a.heather@garvan.org.au
61-292-958-128
Research Australia
Source:Eurekalert

Related medicine news :

1. UGR and Michael J. Fox Foundation take a step forward in the study of Parkinsons disease
2. Chinese Drywall Complaint Center Now Demands Leadership From Obama & EPA, For Homeowners In Florida And In The US Southeast Stuck In Toxic Chinese Drywall Hell-Forward?
3. First-ever Allen Brain Atlas Hackathon unleashes big data API to push neuroscience forward
4. A second victim comes forward in the sexual assault charges filed against Dr. Mike Adam.
5. Study Recommends Putting Your Left Face Forward
6. Study questions the relevance of SCIP benchmarks among CABG patients
7. Pinning protein could answer provocative cancer question
8. Einstein-Montefiore scientists awarded 2 NCI Provocative Questions grants
9. Moffitt Cancer Center researcher receives $2.1 million grant from NCI for answering Provocative Question
10. ACP urges Congress to halt across-the-board sequestration cuts in health programs
11. New HIV/AIDS registry to help answer key questions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs ... College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. ... treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. ...
(Date:6/25/2016)... City, Oklahoma (PRWEB) , ... June 25, 2016 ... ... helping both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic ... the Oklahoma City area —Johnson is one of the first doctors to perform ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, ... and the Road To Recovery® program to drive cancer patients to and from their ... to ensure the highest quality of life and ongoing independence. Getting to and ...
(Date:6/24/2016)... Las Vegas, Nevada (PRWEB) , ... June 24, ... ... their Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and ... The Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... America . ... ... ... ...
(Date:6/23/2016)... 2016  Experian Health, the healthcare industry ... patient payment and care experience, today announced ... and services that will enhance the breadth ... These award-winning solutions will enable healthcare professionals ... in an ever-changing environment and redefine front-office ...
Breaking Medicine Technology: